Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 79,327 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

NCT00990990
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo, Linezolid
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Results available

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions
Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Results available

Intravenous(IV) vs. Erector Spinae Plane Blocks in Cardiac Surgery

NCT04995497
View directory record Official record
Conditions
Erector Spinae Plane Block, Pain Control, Post-Operative Pain, Chronic
Interventions
Intravenous Administration of Lidocaine Post Cardiac Surgery, Administration of Lidocaine Post Cardiac Surgery via ESP Catheter
Drug
Lead sponsor
Archit Sharma
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Nov 7, 2026, 2:35 PM EST
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 7, 2026, 2:35 PM EST
Terminated Phase 2 Interventional Results available

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

NCT00869323
View directory record Official record
Conditions
Lymphoproliferative Disorder
Interventions
rituximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 7, 2026, 2:35 PM EST
Terminated Phase 2 Interventional Results available

Fetal Tracheal Balloon Study in Diaphragmatic Hernia

NCT00966823
View directory record Official record
Conditions
Diaphragmatic Hernia, Lung Disease
Interventions
Fetal tracheal obstruction with detachable balloon (device)
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 7, 2026, 2:35 PM EST
Completed Not applicable Interventional

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

NCT04351880
View directory record Official record
Conditions
Heart Failure, Copd, Liver Failure, Diabetes Mellitus, Cancer, End Stage Renal Disease
Interventions
Medically Tailored Meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Denver, Colorado • Lafayette, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Nov 7, 2026, 2:35 PM EST
Terminated Phase 2 Interventional Results available

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

NCT01649180
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Results available

Bortezomib to Treat Significant Complication of HSCT

NCT01929980
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)
Interventions
Bortezomib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Nov 7, 2026, 2:35 PM EST
Completed Not applicable Interventional

Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)

NCT04536480
View directory record Official record
Conditions
Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Interventions
Time Limited Eating, Components Common to All Study Arms., Control, Continuous Glucose Monitor
Behavioral · Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

NCT01140880
View directory record Official record
Conditions
HIV Seroconversion, Stimulant Abuse
Interventions
Truvada
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 7, 2026, 2:35 PM EST
Not yet recruiting Phase 4 Interventional

Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis

NCT07682662
View directory record Official record
Conditions
Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Interventions
Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
Drug · Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

NCT02753946
View directory record Official record
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Nov 7, 2026, 2:35 PM EST
Terminated Phase 2 Interventional Results available

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

NCT04099888
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
Drug
Lead sponsor
PCI Biotech AS
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 7, 2026, 2:35 PM EST
Completed Not applicable Interventional

Personalized Trial for Chronic Lower Back Pain

NCT04203888
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Swedish Massage, Yoga
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Nov 7, 2026, 2:35 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gestational Weight Gain and Postpartum Weight Loss in Active Duty Women (Moms Fit 2 Fight)

NCT03057808
View directory record Official record
Conditions
Weight Gain, Weight Loss
Interventions
Gestational weight gain intervention, Postpartum weight loss intervention
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 3 Interventional Results available

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT01014208
View directory record Official record
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
OFATUMUMAB + DHAP, RITUXIMAB + DHAP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Sacramento, California • New Haven, Connecticut • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Results available

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

NCT02228525
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
selinexor (KPT-330)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

NCT00390208
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, dexamethasone and verteporfin, Ranibizumab
Drug
Lead sponsor
Bay Area Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Nov 7, 2026, 2:35 PM EST
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Walk With Ease Program for Fall Prevention

NCT05693025
View directory record Official record
Conditions
Exercise, Frailty, Arthritis, Accidental Falls
Interventions
Group Exercise, Behavioral Training
Behavioral
Lead sponsor
Iowa State University
Other
Eligibility
65 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 2 Interventional Results available

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

NCT00858117
View directory record Official record
Conditions
Leukemia
Interventions
Alemtuzumab, Rituximab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Nov 7, 2026, 2:35 PM EST
Active, not recruiting Not applicable Interventional

Dry Needling and Shoulder Muscle Blood Flow, Motions, and Pain Sensitivity in Individuals with Shoulder Pain

NCT05596240
View directory record Official record
Conditions
Dry Needling, Shoulder Pain
Interventions
Dry Needling, Sham Dry Needling
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Nov 7, 2026, 2:35 PM EST
Completed Phase 4 Interventional Results available

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

NCT01382940
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 7, 2026, 2:35 PM EST